Skip to main content

Peer Review reports

From: FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer

Original Submission
10 Aug 2020 Submitted Original manuscript
3 Nov 2020 Reviewed Reviewer Report
7 Jan 2021 Reviewed Reviewer Report
16 Feb 2021 Author responded Author comments - Antoine Adenis
Resubmission - Version 2
16 Feb 2021 Submitted Manuscript version 2
27 Apr 2021 Reviewed Reviewer Report
5 May 2021 Author responded Author comments - Antoine Adenis
Resubmission - Version 3
5 May 2021 Submitted Manuscript version 3
Publishing
6 May 2021 Editorially accepted
17 May 2021 Article published 10.1186/s12885-021-08312-7

You can find further information about peer review here.

Back to article page